Diabetic Gastroparesis Epidemiology Forecast 2026-2035

Diabetic gastroparesis demonstrates a pooled global prevalence of approximately 9.3% among individuals with diabetes, reflecting a significant diabetic gastroparesis prevalence worldwide. The burden is higher in type 2 diabetes (12.5%) compared to type 1 (8.3%), more pronounced in adults under 60 years (15.8%) versus those older (5.5%), and consistently greater among women globally. According to the diabetic gastroparesis epidemiology forecast, these trends highlight a growing disease burden.

Diabetic Gastroparesis Epidemiology Forecast Report Coverage

The analyst's “Diabetic Gastroparesis Epidemiology Forecast Report 2026-2035” offers comprehensive information on the prevalence and demographics of diabetic gastroparesis. It projects the future incidence and prevalence rates of diabetic gastroparesis cases across various populations. The study covers age, gender, and type as major determinants of the diabetic gastroparesis population. The report highlights patterns in the prevalence of diabetic gastroparesis over time and projects future trends based on multiple variables.

The report provides a comprehensive overview of the disease, as well as historical and projected data on the epidemiology of amblyopia in the 8 major markets.

Regions Covered

• The United States
• Germany
• France
• Italy
• Spain
• The United Kingdom
• Japan
• India

Diabetic Gastroparesis Understanding: Disease Overview

Diabetic gastroparesis is a chronic complication of diabetes characterized by delayed gastric emptying without mechanical obstruction, aligning with delayed gastric emptying epidemiology patterns. Symptoms include nausea, vomiting, early satiety, bloating, and abdominal discomfort. It results from autonomic neuropathy affecting gastric motility, commonly in long-standing diabetes. The disorder significantly impacts nutrition, glycemic control, and quality of life, increasing hospitalization and healthcare utilization.

Diabetic Gastroparesis Epidemiology Perspective

The diabetic gastroparesis epidemiology division offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. The analyst provides both current and predicted trends for the diabetic gastroparesis epidemiology scenario by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for diabetic gastroparesis and their trends. The data is broken down into specific categories, such as total prevalent cases in males and females, and total diagnosed cases across different age groups and patient pools.

• Diabetic gastroparesis affects approximately 9.3% of individuals with diabetes worldwide, indicating a significant burden, reflecting a high diabetes-related gastrointestinal disorder burden.
• Prevalence is higher in women compared with men, demonstrating a consistent sex-based pattern, highlighting sex-specific gastroparesis distribution trends globally.
• Among diabetic populations, type 2 diabetes shows higher prevalence than type 1 diabetes, indicating distinct type 2 diabetes gastroparesis risk patterns.
• Diabetic gastroparesis is more common in adults under 60 years compared to older individuals, reflecting age-related gastric motility disorder patterns.

Country-wise Diabetic Gastroparesis Epidemiology

The diabetic gastroparesis epidemiology data and findings for the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.

In the United States, diabetic gastroparesis represents a major contributor within the broader gastroparesis population, reflecting significant gastroparesis disease burden trends. A large population-based analysis reported a standardized prevalence of 267.7 per 100,000 adults, with 57.4% of cases attributed to diabetes. In the United Kingdom, prevalence was 13.8 per 100,000 persons, with diabetes accounting for 37.5% of cases, highlighting its major etiological role.

Diabetic Gastroparesis: Treatment Overview

Management includes dietary modifications, prokinetic agents such as metoclopramide or erythromycin, antiemetics, and glycemic control optimization, reflecting evolving gastroparesis treatment response patterns. In refractory cases, gastric electrical stimulation or enteral feeding may be considered. Emerging therapies, including ghrelin agonists and motilin receptor modulators, are under evaluation. Multidisciplinary care is essential to improve symptom control, nutritional outcomes, and overall quality of life.

Key Questions Answered

• What are the key findings of diabetic gastroparesis epidemiology in the 8 major markets?
• What will be the total number of patients with diabetic gastroparesis across the 8 major markets during the forecast period?
• What was the country-wise diabetic gastroparesis epidemiology scenario in the 8 major markets in the historical period?
• Which country will have the highest number of diabetic gastroparesis patients during the forecast period of 2026-2035?
• Which key factors would influence the shift in the patient population of diabetic gastroparesis during the forecast period of 2026-2035?
• What are the currently available treatments for diabetic gastroparesis?
• What are the disease risks, signs, symptoms, and unmet needs of diabetic gastroparesis?

Scope of the Diabetic Gastroparesis Epidemiology Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of diabetic gastroparesis based on several factors.
• Diabetic Gastroparesis Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
• The diabetic gastroparesis report helps to identify the patient population, and the unmet needs are highlighted along with an assessment of the disease's risk and burden.